晚期肾透明细胞癌靶向治疗的预测因素及预后模型的研究进展
摘要
晚期肾透明细胞癌已经进入了靶向治疗时代,靶向药物可显著延长晚期肾透明细胞患者的无进展生存期(PFS)和总生存期(OS)。单个因素并不能准确的预测患者的预后,将靶向药物治疗前、治疗中及分子生物学等相关预测因素进行整合,建立的纪念斯隆-凯特琳癌症中心(MSKCC)、国际转移性肾细胞癌数据库联盟模型(IMRDC)、国际肾癌工作组(IKCWG)模型、法国模型、克利夫兰医学中心(CCF)等预后模型,可以更准确的预测晚期肾透明细胞癌患者靶向治疗药物的临床疗效,并指导临床治疗。
引文
[1]Lipworth L,Tarone RE,McLaughlin JK.Renal cell cancer among African Americans:an epidemiologic review[J].BMC Cancer,2011,11:133.
[2]Zhang GM,Zhu Y,Gu WJ,et al.Pretreatment neutrophil-tolymphocyte ratio predicts prognosis in patients with metastatic renal cell carcinoma receiving targeted therapy[J].Int J Clin Oncol,2016,21(2):373-378.
[3]Karakiewicz PI,Trinh QD,de Ia Taille A,et al.ECOG performance status 0 or 1 and symptom classification do not improve the ability to predict renal cell carcinoma-specific survival[J].Eur J Cancer,2007,43(6):1023-1029.
[4]Motzer RJ,Bukowski RM,Figlin RA,et al.Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma[J].Cancer,2008,113(7):1552-1558.
[5]Shinohara N,Obara W,Tatsugami K,et al.Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy[J].Cancer Sci,2015,106(5):618-626.
[6]Vickers MM,Al-Harbi H,Choueiri TK,et al.Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy:results rrom the international metastatic renal cell carcinoma database consortium[J].Clin Genitourin Cancer,2013,11(3):311-315.
[7]赵菊平,何骇超,王浩飞,等.舒尼替尼治疗转移性肾癌的预后因素分析[J].中华泌尿外科杂志,2015,36(1):7-11.
[8]Kondo T,Nakazawa H,Oya M,et al.Clinical efficacy and prognostic factors of tumor progression in Japanese patients with advanced renal cell carcinoma treated with sorafenib[J].Jpn J Clin Oncol,2015,45(3):274-280.
[9]Kalra S,Atkinson BJ,Matrana MR,et al.Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases[J].BJU Int,2016,117(5):761-765.
[10]Lacovelli R,Lanoy E,Albiges L,et al.Tumor burden is an independent prognostic factor in metastatic renal cell carcinoma[J].BJU Int,2012,10(11):1747-1753.
[11]Lohse CM,Cheville JC.A review of prognostic pathologic features and algorithms for patients treated surgically for renal cell carcinoma[J].Clin Lab Med,2005,25(2):433-464.
[12]Golshayan AR,George S,Heng DY,et al.Metastatic sarcomatoid renal cell carcinama treated with vascular endothelial growth factor-targeted therapy[J].J Clin Oncol,2009,27(2):235-241.
[13]Schutz FA,Xie W,Donskov F,et al.The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma:results from the international metastatic renal cell cancer database consortium[J].Eur Urol,2014,65(4):723-730.
[14]Heng DY,Xie W,Regan MM,et al.Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents:results from a large,multicenter study[J].JClin Oncol,2009,27:5794-5799.
[15]李宏蕾,冯国伟,林瑞,等.转移性肾癌术前D-二聚体对靶向治疗的预测意义[J].中国肿瘤临床,2016,43(22):992-996.
[16]Inoue R,Kitamura H,Shindo T,et al.Prognostic factors and efficacy of molecular targeted therapy for metastatic clear cell renal cell carcinoma[J].Jpn Soc Endosc Surg,2015,61(4):135-139.
[17]Zhao J,Huang X,Sun F,et al.Prognostic factors for overall survival with targeted therapy in Chinese patients with metastatic renal cell carcinoma[J].Can Urol Assoc J,2014,8(11-12):E821-E827.
[18]Shirotake S,Yasumizu Y,Ito K,et al.Impact of secondline targeted therapy dose intensity on patients with metastatic renal cell carcinoma[J].Clin Genitourina Cancer,2016,14(6):575-583.
[19]FertéC,Koscielny S,Albiges L,et al.Tumor growth rate provides useful inform-ation to evaluate sorafenib and everolimus treatment in metastatic renal cell carc-inoma patients:an integrated analysis of the TARGET and RECORDphase 3 trial data[J].Eur Urol,2014,65(4):713-720.
[20]van der Veldt AA,Meijerink MR,van den Eertwegh AJ,et al.Sunitinib for treatment of advanced renal cell cancer:primary tumor response[J].Clin Cancer Res,2008,14(8):2431-2436.
[21]León L,García-Figueiras R,Suárez C,et al.Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer[J].Targ Oncol,2014,9(1):9-24.
[22]Dienstmann R,Bra馻I,Rodon J,et al.Toxicity as a biomarker of efficacy of molecular targeted therapies:focus on EGFR and VEGF inhibiting anticancer drugs[J].Oncologist,2011,16(12):1729-1740.
[23]Sehmidinger M,Vogl UM,Bojic M,et al.Hypothyroidism in patients with renal cell carcinoma:blessing or curse?[J].Cancer,2011,117:534-544.
[24]Rini BI,Cohen DP,Lu DR,et al.Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib[J].J Natl Cancer Inst,2011,103(9):763-773.
[25]Michaelson MD,Cohen DP,Li S,et al.Hand-foot syndrome(HFS)as a potential biomarker of efficacy in patients(pts)with metastatic renal cell carcinoma(mRCC)treated with sunitinib(SU)[J].Clin Oncol,2011,29(7 suppl):320.
[26]Donskov F,Cams A,Barrios CH,et al.1141 poster neutropenia and thrombocytopenia during treatment as biomarkers of sunitinib efficacy in patients withmetastatic renal cell carcinoma(mRCC)[J].Eur J Cancer,2011,47(Supplement 1):S136.
[27]Deprimo SE,Bello CL,Smeraglia J,et al.Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma:modulation of VEGF and VEGF-related proteins[J].J Transl Med,2007,5:32.
[28]Pantuck AJ,Seligson DB,Klatte T,et al.Prognostic relevance of the mTOR pathway in renal cell carcinoma:implications for molecular patient selection for targeted therapy[J].Cancer,2007,109(11):2257-2267.
[29]Ho TH,Choueiri TK,Wang K,et al.Correlation between molecular subclassifications of clear cell renal cell carcinoma and targeted therapy response[J].Eur Urol Focus,2016,2(2):204-209.
[30]Song Y,Huang J,Shan L,et al.Analyses of potential predictive markers and response to targeted therapy in patients with advanced clear-cell renal cell carcinoma[J].Chin Med J(Engl),2015,128(15):2026-2033.
[31]Stewart GD,O'Mahony FC,Laird A,et al.Carbonic anhydrase9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer[J].Eur Urol,2014,66(5):956-963.
[32]Tran HF,Liu Y,Zurita AJ,et al.Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer:a retrospective analysis of phase 2 and phase 3 trials[J].Lancet Oncol,2012,13(8):827-837.
[33]Motzer RJ,Bacik J,Murphy BA,et al.Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal carcinoma[J].J Clin Oncol,2002,20(1):289-296.
[34]李虹,曾浩,李响,等.靶向分子时代转移性肾癌治疗进展与治疗方案的合理化选择[J].现代泌尿外科杂志,2010,15(5):321-328.
[35]Heng DY,Xie W,Regan MM,et al.External validation and comparison with other models of the international metastatic renal-cell carcinoma database consortium prognostic model:a population-based study[J].Lancet Oncol,2013,14(2):141-148.
[36]Motzer RJ,Bacik J,Schwartz LH,et al.Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma[J].J Clin Oncol,2004,22(3):454-463.
[37]Song Y,Du C,Zhang W,et al.Body mass index and age are additional prognostic factors in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors[J].Urol Oncol,2016,34(6):258.e15-22.
[2]Zhang GM,Zhu Y,Gu WJ,et al.Pretreatment neutrophil-tolymphocyte ratio predicts prognosis in patients with metastatic renal cell carcinoma receiving targeted therapy[J].Int J Clin Oncol,2016,21(2):373-378.
[3]Karakiewicz PI,Trinh QD,de Ia Taille A,et al.ECOG performance status 0 or 1 and symptom classification do not improve the ability to predict renal cell carcinoma-specific survival[J].Eur J Cancer,2007,43(6):1023-1029.
[4]Motzer RJ,Bukowski RM,Figlin RA,et al.Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma[J].Cancer,2008,113(7):1552-1558.
[5]Shinohara N,Obara W,Tatsugami K,et al.Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy[J].Cancer Sci,2015,106(5):618-626.
[6]Vickers MM,Al-Harbi H,Choueiri TK,et al.Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy:results rrom the international metastatic renal cell carcinoma database consortium[J].Clin Genitourin Cancer,2013,11(3):311-315.
[7]赵菊平,何骇超,王浩飞,等.舒尼替尼治疗转移性肾癌的预后因素分析[J].中华泌尿外科杂志,2015,36(1):7-11.
[8]Kondo T,Nakazawa H,Oya M,et al.Clinical efficacy and prognostic factors of tumor progression in Japanese patients with advanced renal cell carcinoma treated with sorafenib[J].Jpn J Clin Oncol,2015,45(3):274-280.
[9]Kalra S,Atkinson BJ,Matrana MR,et al.Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases[J].BJU Int,2016,117(5):761-765.
[10]Lacovelli R,Lanoy E,Albiges L,et al.Tumor burden is an independent prognostic factor in metastatic renal cell carcinoma[J].BJU Int,2012,10(11):1747-1753.
[11]Lohse CM,Cheville JC.A review of prognostic pathologic features and algorithms for patients treated surgically for renal cell carcinoma[J].Clin Lab Med,2005,25(2):433-464.
[12]Golshayan AR,George S,Heng DY,et al.Metastatic sarcomatoid renal cell carcinama treated with vascular endothelial growth factor-targeted therapy[J].J Clin Oncol,2009,27(2):235-241.
[13]Schutz FA,Xie W,Donskov F,et al.The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma:results from the international metastatic renal cell cancer database consortium[J].Eur Urol,2014,65(4):723-730.
[14]Heng DY,Xie W,Regan MM,et al.Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents:results from a large,multicenter study[J].JClin Oncol,2009,27:5794-5799.
[15]李宏蕾,冯国伟,林瑞,等.转移性肾癌术前D-二聚体对靶向治疗的预测意义[J].中国肿瘤临床,2016,43(22):992-996.
[16]Inoue R,Kitamura H,Shindo T,et al.Prognostic factors and efficacy of molecular targeted therapy for metastatic clear cell renal cell carcinoma[J].Jpn Soc Endosc Surg,2015,61(4):135-139.
[17]Zhao J,Huang X,Sun F,et al.Prognostic factors for overall survival with targeted therapy in Chinese patients with metastatic renal cell carcinoma[J].Can Urol Assoc J,2014,8(11-12):E821-E827.
[18]Shirotake S,Yasumizu Y,Ito K,et al.Impact of secondline targeted therapy dose intensity on patients with metastatic renal cell carcinoma[J].Clin Genitourina Cancer,2016,14(6):575-583.
[19]FertéC,Koscielny S,Albiges L,et al.Tumor growth rate provides useful inform-ation to evaluate sorafenib and everolimus treatment in metastatic renal cell carc-inoma patients:an integrated analysis of the TARGET and RECORDphase 3 trial data[J].Eur Urol,2014,65(4):713-720.
[20]van der Veldt AA,Meijerink MR,van den Eertwegh AJ,et al.Sunitinib for treatment of advanced renal cell cancer:primary tumor response[J].Clin Cancer Res,2008,14(8):2431-2436.
[21]León L,García-Figueiras R,Suárez C,et al.Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer[J].Targ Oncol,2014,9(1):9-24.
[22]Dienstmann R,Bra馻I,Rodon J,et al.Toxicity as a biomarker of efficacy of molecular targeted therapies:focus on EGFR and VEGF inhibiting anticancer drugs[J].Oncologist,2011,16(12):1729-1740.
[23]Sehmidinger M,Vogl UM,Bojic M,et al.Hypothyroidism in patients with renal cell carcinoma:blessing or curse?[J].Cancer,2011,117:534-544.
[24]Rini BI,Cohen DP,Lu DR,et al.Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib[J].J Natl Cancer Inst,2011,103(9):763-773.
[25]Michaelson MD,Cohen DP,Li S,et al.Hand-foot syndrome(HFS)as a potential biomarker of efficacy in patients(pts)with metastatic renal cell carcinoma(mRCC)treated with sunitinib(SU)[J].Clin Oncol,2011,29(7 suppl):320.
[26]Donskov F,Cams A,Barrios CH,et al.1141 poster neutropenia and thrombocytopenia during treatment as biomarkers of sunitinib efficacy in patients withmetastatic renal cell carcinoma(mRCC)[J].Eur J Cancer,2011,47(Supplement 1):S136.
[27]Deprimo SE,Bello CL,Smeraglia J,et al.Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma:modulation of VEGF and VEGF-related proteins[J].J Transl Med,2007,5:32.
[28]Pantuck AJ,Seligson DB,Klatte T,et al.Prognostic relevance of the mTOR pathway in renal cell carcinoma:implications for molecular patient selection for targeted therapy[J].Cancer,2007,109(11):2257-2267.
[29]Ho TH,Choueiri TK,Wang K,et al.Correlation between molecular subclassifications of clear cell renal cell carcinoma and targeted therapy response[J].Eur Urol Focus,2016,2(2):204-209.
[30]Song Y,Huang J,Shan L,et al.Analyses of potential predictive markers and response to targeted therapy in patients with advanced clear-cell renal cell carcinoma[J].Chin Med J(Engl),2015,128(15):2026-2033.
[31]Stewart GD,O'Mahony FC,Laird A,et al.Carbonic anhydrase9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer[J].Eur Urol,2014,66(5):956-963.
[32]Tran HF,Liu Y,Zurita AJ,et al.Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer:a retrospective analysis of phase 2 and phase 3 trials[J].Lancet Oncol,2012,13(8):827-837.
[33]Motzer RJ,Bacik J,Murphy BA,et al.Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal carcinoma[J].J Clin Oncol,2002,20(1):289-296.
[34]李虹,曾浩,李响,等.靶向分子时代转移性肾癌治疗进展与治疗方案的合理化选择[J].现代泌尿外科杂志,2010,15(5):321-328.
[35]Heng DY,Xie W,Regan MM,et al.External validation and comparison with other models of the international metastatic renal-cell carcinoma database consortium prognostic model:a population-based study[J].Lancet Oncol,2013,14(2):141-148.
[36]Motzer RJ,Bacik J,Schwartz LH,et al.Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma[J].J Clin Oncol,2004,22(3):454-463.
[37]Song Y,Du C,Zhang W,et al.Body mass index and age are additional prognostic factors in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors[J].Urol Oncol,2016,34(6):258.e15-22.